⚕️The British Research Panel highlights patient recruitment as a significant challenge in clinical trials, leading to delays in drug approvals and increased costs for sponsors. Lack of awareness among the public is a key issue, with 75% of patients unsure how to find a clinical trial. 💊uMed's innovative patient recruitment approach leverages a network of 6 million electronic health records to connect researchers with clinically validated patients efficiently. This ensures patients are informed about relevant research opportunities that align with their needs. 🩺Having facilitated the recruitment of over 5,000 patients for groundbreaking research since 2018, uMed continues to address crucial drug development challenges across various disease areas. Collaborating with key stakeholders, uMed is at the forefront of overcoming patient recruitment barriers. 👩💻For those looking to enhance patient recruitment strategies, reach out to me at Sian@umed.io to discover how uMed can accelerate your clinical trials. #uMed #ClinicalTrials #PatientRecruitment #PatientCentricity
Sian Organ’s Post
More Relevant Posts
-
As many as 80% of clinical trials face patient recruitment challenges (to say nothing of patient retention), adding time and cost to clinical trials. The European Clinical Trials Information Network’s new pan-European platform should help. The network, which will connect patients with rare and serious diseases with research centers recruiting for clinical trials, should help enable more decentralized clinical trials on the continent—an increasingly popular trial format in the U.S. that’s struggled to catch on here. It will take time to bear fruit, but the result should be more efficient, more inclusive trials at lower cost. #clinicaltrials #pharma #DCT
To view or add a comment, sign in
-
Attention Clinical Trial Sponsors! 🔬 Are you seeking high-performing sites for your next #Psoriasis study? Partner with #ProbityMedicalResearch to gain access to a vast network of top-tier clinical sites across Canada and beyond. Our experienced teams are dedicated to delivering exceptional results. Connect with us today to take your #clinicaltrials to the next level! Click on the link in the comments to learn more and connect right away! #ClinicalResearch #PsoriasisAwarenessMonth #PsoriasisResearch #PMR
To view or add a comment, sign in
-
❓ Does involving patients in drug development really make a difference? 🔍 Involving patients isn’t just a trend—it’s a game-changer. Patient insights help shape clinical trials, making them more relevant and ensuring therapies meet real-world needs. At 3D-PharmXchange, we’re committed to working closely with patient advocacy groups and innovators to co-create treatments that genuinely impact patient lives. 💡 Curious about how patient advocacy is driving progress, especially in rare disease research? Check out our latest blog to learn more: https://lnkd.in/ek6KbMCq #DrugDevelopment #Pharma #ClinicalTrials #PatientAdvocacy #OrphanDiseases #RareDiseases #PatientEngagement #HealthInnovation #LifeSciences #PrecisionMedicine #TherapeuticDevelopment #ClinicalResearch #PatientExperience #HealthCareInnovation #MedicalResearch #DrugDiscovery #PatientVoice Pivot Park Leiden Bio Science Park Amsterdam Science Park - Science & Business organisation Health & Innovation District Amsterdam (Hid) Amsterdam UMC Rotterdam Square Universitair Medisch Centrum Utrecht UMCG Maastricht UMC+ Radboudumc
To view or add a comment, sign in
-
🔬 Unraveling the Placebo-Adherence Enigma in Clinical Trials 🔬 Exciting new insights emerge from our latest blog post "Placebo And Adherence: Is A Complicated Relationship Compromising Clinical Trial Effectiveness?" Highlighting a century of mystery since T.C. Graves first defined the placebo effect, we delve into the nuanced relationship between adherence and placebo responses in clinical trials. Our article explores pivotal findings, starting with the landmark Coronary Drug Project Research Group study in 1980, which first linked adherence rates to mortality differences, even among placebo groups. This intriguing correlation challenges conventional trial methodologies and prompts a deeper look into how we measure and interpret adherence in clinical settings. With cutting-edge analyses and recent advancements in digital monitoring, we're poised to refine our understanding of the 'healthy adherer' effect and enhance trial integrity. Join us as we discuss how these insights could revolutionize clinical trial outcomes and potentially recalibrate regulatory approaches. 📈 Dive into our comprehensive analysis here: https://hubs.li/Q02vt-JV0 #ClinicalTrials #PlaceboEffect #HealthcareInnovation #Adherence #MedicalResearch
To view or add a comment, sign in
-
𝐈𝐧 𝐩𝐞𝐝𝐢𝐚𝐭𝐫𝐢𝐜 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬, 𝐭𝐡𝐞 𝐢𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐨𝐟 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐫𝐞𝐩𝐨𝐫𝐭𝐞𝐝 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 (𝐏𝐑𝐎𝐬) 𝐚𝐬 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞 𝐦𝐞𝐚𝐬𝐮𝐫𝐞 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐚𝐥𝐚𝐫𝐦𝐢𝐧𝐠𝐥𝐲 𝐥𝐨𝐰. In 2021, only 8.2% of trials included PROs as either a primary or secondary endpoint, with just 0.6% using PROs as a primary outcome. 👨👩👦 This reveals a significant gap in clinical research—there is a cruel lack of direct patient and caregiver input in how we measure drug efficacy and safety. 👉 It’s time to prioritize patient-centered research that truly reflects the needs and experiences of those who matter most—the patients and their families. SOURCE: https://bit.ly/3ZE47Hi #BehindTheClinicalTrials #eCOA #kayentis #clinicalstudies
To view or add a comment, sign in
-
🚀 Exploring the Future of Pharmacogenomic Testing (PGx) in Primary Care! 🚀 Pharmacogenomic testing (PGx) has incredible potential to enhance patient safety by personalizing medication treatments. However, as recent research highlights, there are significant challenges to its integration in primary care settings. 🔹 The Study: A systematic review of 78 studies revealed both **enablers** and **obstacles** for PGx implementation: - **Enablers**: Diagnostic and therapeutic benefits, cost reduction, and empowering healthcare professionals. - **Challenges**: Lack of scientific evidence, insufficient training, ethical and legal concerns, low patient awareness, and high costs. 🔹 **Key Takeaways**: - To effectively implement PGx in primary care, we need increased consumer awareness, comprehensive provider training on ethical/legal aspects, and global feasibility studies. - Addressing high costs will require process optimization, advocating for reimbursement policies, and investing in affordability research. **Integrating PGx in primary care could redefine healthcare standards and improve life expectancy.** Let’s continue investing in innovative solutions to bring these benefits to patients everywhere! Special thanks to Dr Keivan Armani, Dr Dr. Sathvik Sridhar, Dr Javedh Shareef, Dr Chun-Wai Mai #Pharmacogenomics #HealthcareInnovation #PrimaryCare #PatientSafety #Research
To view or add a comment, sign in
-
How are companies in the psychedelics space overcoming clinical trial challenges? Our latest insight dives into the key strategies companies are adopting and sheds light on the evolving landscape of psychedelic clinical trials. Read the full article today: https://bit.ly/3CElvT5 #psychedelics #clinicaltrials #healthcare #lifesciences #LEKLifeSciences
Clinical Trial Design Strategies To Address Methodological Challenges in Psychedelics | L.E.K. Consulting
lek.com
To view or add a comment, sign in
-
I am thrilled that Sophie Wintrich could be part of a dynamic panel session at the recent TransPerfect Life Sciences C3 Summit. "How can patients be partners to industry, to elevate the patient voice to drive real and impactful change?" See the key takeaways below! www.patient-co-next.com #patientengagement #patientcentricity #patientadvocacy #clinicaltrials #research #drugdevelopment #patientinsights #patientrecruitment #clinicaloperations #pfmd #patientjourney #healthliteracy #patientinformation
How can patients be partners to industry, to elevate the patient voice to drive real and impactful change? Our Patient Advocacy Connector, Sophie Wintrich, was at the TransPerfect Life Sciences C3 Summit on 2 May, 2024 in London to discuss this with a dynamic group of panelists. Key takeaways: 📱Information shared with patients at recruitment stage needs a revamp, and must go beyond the clinicaltrials.gov format. Greater transparency in actual benefits (and risks) that patients can expect, and in language they can comprehend, is needed. 👩🏻🦰Not including patients as equal decision partners at every stage of drug development, creates a 'domino effect' which will impact the trial later on - notably impacting recruitment, retainment, and data quality. 🤲 Patient support groups should be involved early as possible in drug development and clinical trials. 💁🏻♀️Patient support groups themselves need more support to effectively help the industry and trial sponsors shape better clinical trials. 😏Although there was good consensus among individuals in Biopharma that patient engagement was important and could save time and money, these often are expressed as 'personal' views and lacking company-wide implementation. We would love to know your thoughts! Connect with us! www.patient-co-next.com sophie@patient-co-next.com pauline@patient-co-next.com #patientengagement #patientcentricity #patientadvocacy #clinicaltrials #research #drugdevelopment #patientinsights #patientrecruitment #clinicaloperations #pfmd #patientjourney #healthliteracy #patientinformation
To view or add a comment, sign in
-
How can patients be partners to industry, to elevate the patient voice to drive real and impactful change? Our Patient Advocacy Connector, Sophie Wintrich, was at the TransPerfect Life Sciences C3 Summit on 2 May, 2024 in London to discuss this with a dynamic group of panelists. Key takeaways: 📱Information shared with patients at recruitment stage needs a revamp, and must go beyond the clinicaltrials.gov format. Greater transparency in actual benefits (and risks) that patients can expect, and in language they can comprehend, is needed. 👩🏻🦰Not including patients as equal decision partners at every stage of drug development, creates a 'domino effect' which will impact the trial later on - notably impacting recruitment, retainment, and data quality. 🤲 Patient support groups should be involved early as possible in drug development and clinical trials. 💁🏻♀️Patient support groups themselves need more support to effectively help the industry and trial sponsors shape better clinical trials. 😏Although there was good consensus among individuals in Biopharma that patient engagement was important and could save time and money, these often are expressed as 'personal' views and lacking company-wide implementation. We would love to know your thoughts! Connect with us! www.patient-co-next.com sophie@patient-co-next.com pauline@patient-co-next.com #patientengagement #patientcentricity #patientadvocacy #clinicaltrials #research #drugdevelopment #patientinsights #patientrecruitment #clinicaloperations #pfmd #patientjourney #healthliteracy #patientinformation
To view or add a comment, sign in
-
When it comes to pediatric clinical trials, one question stands out: Are we truly listening to the voices that matter most? Despite the advancements in clinical research, only 8.2% of pediatric trials in 2021 included patient-reported outcomes (PROs) as a primary or secondary endpoint, and a mere 0.6% used them as a primary outcome. This isn’t just a statistic—it’s a missed opportunity to understand the full impact of treatments on young patients and their families. Children in clinical trials face unique challenges, and their lived experiences—like treatment side effects, quality of life, and emotional well-being—are critical indicators of success. Without capturing this data, are we painting a complete picture of drug efficacy and safety? At Kayentis, we see this as a call to action. By embedding PROs into trial design, we can transform patient care, ensuring that every child’s voice helps shape the future of treatment. It’s time to challenge the status quo and reimagine pediatric trials to prioritize what truly matters: the patient’s perspective. #PediatricTrials #PatientVoice #ClinicalResearch #eCOA
𝐈𝐧 𝐩𝐞𝐝𝐢𝐚𝐭𝐫𝐢𝐜 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬, 𝐭𝐡𝐞 𝐢𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐨𝐟 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐫𝐞𝐩𝐨𝐫𝐭𝐞𝐝 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 (𝐏𝐑𝐎𝐬) 𝐚𝐬 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞 𝐦𝐞𝐚𝐬𝐮𝐫𝐞 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐚𝐥𝐚𝐫𝐦𝐢𝐧𝐠𝐥𝐲 𝐥𝐨𝐰. In 2021, only 8.2% of trials included PROs as either a primary or secondary endpoint, with just 0.6% using PROs as a primary outcome. 👨👩👦 This reveals a significant gap in clinical research—there is a cruel lack of direct patient and caregiver input in how we measure drug efficacy and safety. 👉 It’s time to prioritize patient-centered research that truly reflects the needs and experiences of those who matter most—the patients and their families. SOURCE: https://bit.ly/3ZE47Hi #BehindTheClinicalTrials #eCOA #kayentis #clinicalstudies
To view or add a comment, sign in